Xarelto, the new anticoagulant treatment from Bayer has been launched in the UK, and is set to be among a …
Interim management is now a popular choice in pharma marketing, both for companies looking to recruit for short spells, and …
Acomplia's EU suspension dispels illusion of blockbuster futureThe EMEA has suspended Acomplia due to the risk of serious psychiatric disorders. …
Healthcare provision should increasingly be modelled along social enterprise lines, according to the NHS Alliance. Not-for-profit groups of out-of-hours providers …
Strong sales of Bayer's Yaz contraceptives and multiple sclerosis treatment Betaferon have helped third quarter pharma sales that could only …
New data shows Roche's Actemra (tocilizumab) increases the disease remission rate in rheumatoid arthritis (RA) sufferers. The company says the …
The companies behind Alzheimer's drug Aricept have won the right to see the economic model NICE used to assess the …
Novartis' development drug ACZ885 (canakinumab) has turned in impressive results in trials for rare medical conditions. It showed sustained remission …
GlaxoSmithKline is to pay $57 million (£35 million) for Genelabs, California-based specialists in infectious diseases, including hepatitis C. The companies …
From the middle of the last century, the likes of GSK, Pfizer, AstraZeneca, Bristol Myers Squibb and others have made …
How did you find your way into your role?
Targeted therapy cancer brands to achieve sales of over $42 billion by 2017Targeted therapies have improved treatment outcomes in cancer …
Novartis has shaken up its senior management structure with the creation of a new post – chief operating officer. From …
Merck has announced a new round of job cuts and restructuring in a bid to update its business model and …
Roche's sales dropped 2% to 33.3 billion Swiss francs in the first nine months of 2008, due to a sharp …
Bioscience leaders from both sides of the Atlantic have joined in a war game that could help boost the UK …
Talks on the future of pharmaceutical pricing scheme the PPRS have stumbled into trouble, after it emerged a major part …
The relationship between doctors and the pharmaceutical industry has attracted considerable criticism in the past five years. Scepticism has risen, …